The invention pertains to a therapeutic, prophylactic or diagnostic method comprising, administering a pharmaceutical compound followed by administering a biocompatible nanoparticle comprising an oligomer of albumin, wherein the longest or largest dimension of the nanoparticle is between about 4 nm and about 500 nm. In preferred embodiments, administering the biocompatible nanoparticles is performed between more than 5 minutes and about 72 hours after administering the pharmaceutical compound. In particular embodiments, the pharmaceutical compound is a pharmaceutical antibody, such as a monoclonal antibody, a drug conjugated antibody, an engineered antibody and a multispecific antibody. According to the methods of the invention, administering the biocompatible nanoparticle comprising oligomers of albumin after administering the pharmaceutical compound maintains or increases the therapeutic benefit and reduces toxicity of the pharmaceutical compound when compared to the therapeutic benefit and toxicity induced by administering the pharmaceutical compound alone.
